The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.
 
Valentina Marulanda Corzo
No Relationships to Disclose
 
Charlene Thomas
Travel, Accommodations, Expenses - Inovio Pharmaceuticals; Nektar; Pfizer
 
Gabriel Raab
No Relationships to Disclose
 
Aaron Holmes
No Relationships to Disclose
 
Tobechukwu Okobi
No Relationships to Disclose
 
Andres Ricaurte Fajardo
No Relationships to Disclose
 
Amie Patel
No Relationships to Disclose
 
Zachary Davidson
No Relationships to Disclose
 
Samuel Ruder
No Relationships to Disclose
 
Pier VItale Nuzzo
No Relationships to Disclose
 
Divya Yadav
No Relationships to Disclose
 
Sandra Huicochea Castellanos
No Relationships to Disclose
 
David Nanus
Honoraria - Genentech
Consulting or Advisory Role - AstraZeneca; Janssen Scientific Affairs
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Sagimet Biosciences (Inst); Zenith Epigenetics (Inst)
 
Neil Bander
Employment - Convergent Therapeutics
Leadership - Convergent Therapeutics; XenImmune Therapeutics
Stock and Other Ownership Interests - Convergent Therapeutics; XenImmune Therapeutics
Patents, Royalties, Other Intellectual Property - Patents to anti-PSMA antibodies assigned to Cornell Univ; Royalty--Cook Urological
 
Joseph Osborne
Honoraria - Siemens Healthineers
Consulting or Advisory Role - Siemens Healthineers
Travel, Accommodations, Expenses - Siemens Healthineers
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics